Overview

Phase IIIB Subcutaneous Abatacept Monotherapy Study

Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
To evaluate safety and immunogenicity of abatacept when used with or without methotrexate in the absence of an IV loading dose of abatacept
Phase:
Phase 3
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Abatacept
Methotrexate